Director/PDMR Shareholding

Dr Martens

12/12/2025 07:00

RNS Number : 2899L

Dr. Martens PLC

12 December 2025

 

Dr. Martens plc (the 'Company')

Director/PDMR Shareholding

Notification of Transaction by Director/Person Discharging Managerial Responsibility

The Company announces that it has been notified that Robert Hanson, Independent Non-Executive Director and PDMR, purchased 104,000 ordinary shares of 1 pence each in the Company ('Ordinary Shares') on 11 December 2025 at a price of £0.7695 per Ordinary Share.

The relevant notification, set out below, is provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.

 

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Robert Hanson
2
Reason for the notification
a)
Position/status
PDMR (Independent Non-Executive Director)
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Dr. Martens plc
b)
LEI
213800QPT8YM6NQZPH28
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary shares of GBP 0.01

 ISIN: GB00BL6NGV24
b)
Nature of the transaction
Purchase of Ordinary Shares
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£0.7695
104,000
d)
Aggregated information
-
Aggregated volume
-
Price
Single transaction
e)
Date of the transaction
11 December 2025
f)
Place of the transaction
London Stock Exchange (XLON)

 

For further information please contact:

 

Bethany Barnes

Director of Investor Relations and Corporate Communications

bethany.barnes@drmartens.com

+4478 2518 7465

 

Paul Rolling

Head of Secretariat

paul.rolling@drmartens.com

+4475 8424 3562

                            

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHUASRRVVUUAUA